Biohaven Stock Catapults On A Surprise FDA Move Why It Might Not Be Done Running
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole.
ETH-4.25%
BTC-3.65%
SOL-4.31%
XRP-6.31%
USDC+0.05%
DOGE-5.18%
SUI-6.54%
HYPE-5.29%ETH-4.25%BTC-3.65%SOL-4.31%XRP-6.31%USDC+0.05%DOGE-5.18%SUI-6.54%HYPE-5.29%ETH-4.25%BTC-3.65%SOL-4.31%XRP-6.31%USDC+0.05%DOGE-5.18%SUI-6.54%HYPE-5.29%ETH-4.25%BTC-3.65%SOL-4.31%XRP-6.31%USDC+0.05%DOGE-5.18%SUI-6.54%HYPE-5.29%
